The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

Thanks to a Takeda approval Thursday, patients now have a drug to tackle a rare inherited blood clotting disorder. The U.S. FDA has given a green light to Takeda’s Adzynma, the first recombinant ...

Researchers from the Second Affiliated Hospital of Nanjing Medical University, et al. have published a case report entitled "Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with ...

A woman has been honoured for her work supporting others living with a rare blood disorder. Jo McIntyre, founder of ...

The 3-year relapse and mortality rates for thrombotic thrombocytopenic purpura (TTP) were 23.6% and 26.3%, predicated on platelet count. Platelet count was found to be a predictor of relapse in ...

Jo McIntyre, founder of TTPNetwork and a former domestic abuse reduction coordinator, has been awarded the British Empire Medal (BEM) in the King’s New Year Honours. The award recognises her 28 years ...

Every day, Sanofi employees work to chase the miracles of science and improve people’s lives by asking themselves “what if?” Our work is rooted in scientific curiosity centered on the question: What ...